David J. VanderWeele, Ph.D.
Affiliations: | 2005 | University of Chicago, Chicago, IL |
Area:
Molecular BiologyGoogle:
"David VanderWeele"Parents
Sign in to add mentor| Charles Rudin | grad student | 2005 | Chicago | |
| (The Akt -mTOR signaling pathway mediates resistance to microtubule-directed chemotherapeutic agents.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| VanderWeele DJ, Kocherginsky M, Munir S, et al. (2022) A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer |
| VanderWeele DJ, Hussain M. (2020) PARP inhibitors in prostate cancer: practical guidance for busy clinicians. Clinical Advances in Hematology & Oncology : H&O. 18: 808-815 |
| Adelaiye-Ogala R, Gryder BE, Nguyen YTM, et al. (2020) Targeting the PI3K/AKT pathway overcomes enzalutamide resistance by inhibiting induction of the glucocorticoid receptor. Molecular Cancer Therapeutics |
| Wilkinson S, Harmon SA, Terrigino NT, et al. (2020) A case report of multiple primary prostate tumors with differential drug sensitivity. Nature Communications. 11: 837 |
| Meeks JJ, Shilatifard A, Miller SD, et al. (2020) A pilot study of tazemetostat and MK-3475 (pembrolizumab) in advanced urothelial carcinoma (ETCTN 10183). Journal of Clinical Oncology. 38: TPS607-TPS607 |
| Numan Y, Zhao J, Tang S, et al. (2020) Chemokine signaling and MAPK/ERK pathway for advanced prostate cancer treatment response. Journal of Clinical Oncology. 38: TPS275-TPS275 |
| Burns MC, Sagar V, Jovanovic B, et al. (2020) A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 38: TPS274-TPS274 |
| Wilkinson SC, Ye H, Terrigino N, et al. (2020) Multiple primary prostate tumors with differential drug sensitivity. Journal of Clinical Oncology. 38: 342-342 |
| Boettcher AN, Usman A, Morgans A, et al. (2019) Past, Current, and Future of Immunotherapies for Prostate Cancer. Frontiers in Oncology. 9: 884 |
| VanderWeele DJ, Antonarakis ES, Carducci MA, et al. (2019) Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901595 |